These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35584337)

  • 1. Hematopoietic Stem-Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population-Level Analysis of Statewide Claims Data.
    Waheed A; Rodday AM; Kumar AJ; Miller KB; Parsons SK
    JCO Clin Cancer Inform; 2022 May; 6():e2100135. PubMed ID: 35584337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
    Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
    J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Kako S; Izutsu K; Kato K; Kim SW; Mori T; Fukuda T; Kobayashi N; Taji H; Hashimoto H; Kondo T; Sakamaki H; Morishima Y; Kato K; Suzuki R; Suzumiya J;
    Am J Hematol; 2015 Feb; 90(2):132-8. PubMed ID: 25382792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States.
    Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
    Clin Ther; 2017 Feb; 39(2):303-310. PubMed ID: 28065438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
    Ron-Magaña AL; Fernandez-Vargas OE; Barrera-Chairez E; Ron-Guerrero CS; Bañuelos-Ávila AJ
    Ann Transplant; 2019 Oct; 24():584-587. PubMed ID: 31636248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
    Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
    Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
    Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M
    Med Oncol; 2013; 30(3):611. PubMed ID: 23702734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting.
    Kumar AJ; Chao CR; Rodday AM; Chang H; Xu L; Evens AM; Parsons SK
    Leuk Lymphoma; 2022 May; 63(5):1119-1126. PubMed ID: 34886751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of early infections and predictors of mortality after autologous hematopoietic stem-cell transplantation among multiple myeloma, Hodgkin, and non-Hodgkin lymphoma: the first experience from Palestine.
    Amer R; Salameh H; Mosleh S; Abu-Taha A; Hamayel H; Enaya A; Adas A; Khursani A; Wild-Ali M; Mousa T; Battat M; Daifallah A; Koni A; Shawahna R
    BMC Infect Dis; 2022 Sep; 22(1):725. PubMed ID: 36071381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.
    Casulo C; Arcila M; Bohn OL; Teruya-Feldstein J; Maragulia J; Moskowitz CH
    Leuk Res; 2013 Sep; 37(9):1178-83. PubMed ID: 23706570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
    Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
    Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
    Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
    Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel treatment options in relapsed and refracter Hodgkin lymphomas].
    Illés Á; Jóna Á; Simon Z; Udvardy M; Miltényi Z
    Orv Hetil; 2015 Nov; 156(45):1824-33. PubMed ID: 26522856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.
    Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
    Hematol Oncol; 2020 Dec; 38(5):737-741. PubMed ID: 32905626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
    Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.